default author photo

Li Liu

Central South University - Hunan Cancer Hospital

Changsha, 410013

China

SCHOLARLY PAPERS

1

DOWNLOADS

20

TOTAL CITATIONS

0

Scholarly Papers (1)

1.

Sintilimab Plus Docetaxel as Second-Line Therapy of Advanced Non-Small Cell Lung Cancer Without Targetable Mutations: A Phase II Efficacy and Biomarker Study

Number of pages: 28 Posted: 25 Apr 2022
Central South University - Department of Medical Oncology, Central South University - Department of Medical Oncology, Central South University - Department of Medical Oncology, Central South University - Hunan Cancer Hospital, Central South University - Hunan Cancer Hospital, Central South University - Hunan Cancer Hospital, Central South University - Hunan Cancer Hospital, Central South University - Hunan Cancer Hospital, Shanghai Jiao Tong University (SJTU) - State Key Laboratory of Oncogenes and Related Genes, Central South University - Hunan Cancer Hospital, Qinghai Provincial People's Hospital - Department of Medical Oncology and Central South University - Department of Medical Oncology
Downloads 20 (1,459,862)

Abstract:

Loading...

Sintilimab plus docetaxel, NSCLC, CTC-PD-L1, multiplex immunofluorescence